ArticleCancer biomarkers : section A of Disease markers2019
Identification of biomarkers associated with progression and prognosis in bladder cancer via co-expression analysis.
Article in Cancer biomarkers : section A of Disease markers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- Identification and validation of a novel signature based on M2 macrophage co-expressed genes in bladder cancer.Translational cancer research · 2025Article
- COL6A1 Inhibits the Malignant Development of Bladder Cancer by Regulating FBN1.Cell biochemistry and biophysics · 2025Article
- Article
- CCNB1 is involved in bladder cancer pathogenesis and silencing CCNB1 decelerates tumor growth and improves prognosis of bladder cancer.Experimental and therapeutic medicine · 2023Article
- Weighted Gene Co-Expression Network Analysis of Oxymatrine in Psoriasis Treatment.Journal of inflammation research · 2023Article
- Tumor suppressive role of microRNA-139-5p in bone marrow mesenchymal stem cells-derived extracellular vesicles in bladder cancer through regulation of the KIF3A/p21 axis.Cell death & disease · 2022Article
- Article
- Deoxyschizandrin Inhibits the Proliferation, Migration, and Invasion of Bladder Cancer Cells through ALOX5 Regulating PI3K-AKT Signaling Pathway.Journal of immunology research · 2022Article
- A novel pyroptosis-related prognostic lncRNAs signature, tumor immune microenvironment and the associated regulation axes in bladder cancer.Frontiers in genetics · 2022Article
- Identification of glycolysis genes signature for predicting prognosis in malignant pleural mesothelioma by bioinformatics and machine learning.Frontiers in endocrinology · 2022Article
- Orthodenticle homeobox OTX1 is a potential prognostic biomarker for bladder cancer.Bioengineered · 2021Article
- An Integrated Data Analysis of mRNA, miRNA and Signaling Pathways in Pancreatic Cancer.Biochemical genetics · 2021Article
- A pancancer overview of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer.Oncology letters · 2021Article
- Prognostic signatures associated with high infiltration of Tregs in bone metastatic prostate cancer.Aging · 2021Article
- LINC-PINT Inhibited Malignant Progression of Bladder Cancer by Targeting miR-155-5p.Cancer management and research · 2021Article
- Identification of prognostic biomarkers associated with stromal cell infiltration in muscle-invasive bladder cancer by bioinformatics analyses.Cancer medicine · 2020Article
- Article
- Functional and genomic characterization of three novel cell lines derived from a metastatic gallbladder cancer tumor.Biological research · 2020Article
- Plasma proteomic signature of the risk of developing mobility disability: A 9-year follow-up.Aging cell · 2020Article
- In silico analysis of the immune microenvironment in bladder cancer.BMC cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBladder cancer is one of the most common genitourinary malignancies, with a high rate of recurrence and progression. The prognosis for patients with bladder cancer, especially muscle-invasive bladder cancer, remains poor despite systemic therapy.
objectiveTo explore the underlying disease mechanisms and identify more effective biomarkers for bladder cancer.
methodsWeighted gene co-expression network analysis (WGCNA) and protein-protein interaction (PPI) network analysis were applied to identify hub genes correlated with the bladder cancer progression. Survival analyses were then conducted to identify potential biomarkers correlated with the prognosis of bladder cancer. Finally, validation and analysis of these potential biomarkers were conducted by a series of bioinformatics analyses.
resultsBased on the results of weighted gene co-expression network analysis and protein-protein interaction network analysis, ten hub genes closely correlated with bladder cancer progression were identified in the relevant module. Survival analyses of these genes indicated that elevated expressions of six potential biomarkers (COL3A1, FN1, COL5A1, FBN1, COL6A1 and THBS2) were significantly associated with a worse overall survival. Furthermore, these 6 potential biomarkers were validated in association with the progression of bladder cancer. Bladder cancer samples with higher expression of these genes were most significantly enriched in gene set associated with ECM-receptor interaction.
conclusionsThis study identified several biomarkers associated with bladder cancer progression and prognosis. As novel findings, these may have important clinical implications for diagnosis, treatment and prognosis prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.